Charles J Bieberich

Prof. Charles J Bieberich


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Cancer Cell
Verified
Journal Article
Closed access
KPKarita Peltonen
Karita Peltonen
LCLaureen Colis
Laureen Colis
HLHester Liu
Hester Liu
RTRishi Trivedi
Rishi Trivedi
MMMichael S. Moubarek
Michael S. Moubarek
MLMarikki Laiho
Marikki Laiho

1 August 2010 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
BGBora Gurel
Bora Gurel
TATehmina Z. Ali
Tehmina Z. Ali
EMElizabeth A. Montgomery
Elizabeth A. Montgomery
SBShahnaz Begum
Shahnaz Begum
JHJessica Ba Hicks
Jessica Ba Hicks
AMAngelo M. De Marzo
Angelo M. De Marzo
NKX3.1 is a prostatic tumor suppressor gene located on chromosome 8p. Although most studies have shown that staining for NKX3.1 protein is positive in the majority of primary prostatic adenocarcinomas, it has been shown to be downregulated in many high-grade prostate cancers, and completely lost in the majority of metastatic prostate cancers (eg, in 65% to 78% of lesions). A recent study showed that NKX3.1 staining with a novel antibody was highly sensitive and specific for high-grade prostatic adenocarcinoma when compared with high-grade urothelial carcinoma. This raised the question that this antibody may perform better than earlier used antibodies in metastatic prostate tumors. However, the sensitivity and specificity for prostate carcinomas for this antibody in metastatic lesions was not determined. Although prostate-specific antigen (PSA) and prostatic-specific acid phosphatase (PSAP) are excellent tissue markers of prostate cancer, at times they may be expressed at low levels, focally, or not at all in poorly differentiated primary and metastatic prostatic adenocarcinomas. The purpose of this study was to determine the performance of NKX3.1 as a marker of metastatic adenocarcinoma of prostatic origin. Immunohistochemical staining against NKX3.1, PSA, and PSAP was carried out on a tissue microarray (TMA) (0.6-mm tissue cores) of hormone naïve metastatic prostate adenocarcinoma specimens from lymph nodes, bone, and soft tissue. To determine the specificity of NKX3.1 for prostatic adenocarcinoma, we used TMAs that contained cancers from various sites including the urinary bladder, breast, colon, salivary gland, stomach, pancreas, thyroid, and central nervous system, and standard paraffin sections of cancers from other sites including the adrenal cortex, kidney, liver, lung, and testis. Overall 349 nonprostatic tumors were evaluated. Any nuclear staining for NKX3.1 was considered positive and the percentage of cells with nuclear staining and their mean intensity level were assessed visually. Sensitivity was calculated by considering a case positive if any TMA core was positive. The sensitivity for identifying metastatic prostatic adenocarcinomas overall was 98.6% (68/69 cases positive) for NKX3.1, 94.2% (65/69 cores positive) for PSA, and 98.6% (68/69 cores positive) for PSAP. The specificity of NKX3.1 was 99.7% (1/349 nonprostatic tumors positive). The sole positive nonprostatic cancer case was an invasive lobular carcinoma of the breast. NKX3.1 seems to be a highly sensitive and specific tissue marker of metastatic prostatic adenocarcinoma. In the appropriate clinical setting, the addition of IHC staining for NKX3.1, along with other prostate-restricted markers, may prove to be a valuable adjunct to definitively determine prostatic origin in poorly differentiated metastatic carcinomas.

1 June 2010 in Genes & Cancer
Verified
Journal Article
Closed access
CKC. M. Koh
C. M. Koh
CBCharles J Bieberich
Charles J Bieberich
CDC. V. Dang
C. V. Dang
WNW. G. Nelson
W. G. Nelson
SYS. Yegnasubramanian
S. Yegnasubramanian
AMA. M. De Marzo
A. M. De Marzo
Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial cancer affecting a majority of elderly men in Western nations. Its manifestation, however, varies from clinically asymptomatic insidious neoplasms that progress slowly and do not threaten life to one that is highly aggressive with a propensity for metastatic spread and lethality if not treated in time. A number of somatic genetic and epigenetic alterations occur in prostate cancer cells. Some of these changes, such as loss of the tumor suppressors PTEN and p53, are linked to disease progression. Others, such as ETS gene fusions, appear to be linked more with early phases of the disease, such as invasion. Alterations in chromosome 8q24 in the region of MYC have also been linked to disease aggressiveness for many years. However, a number of recent studies in human tissues have indicated that MYC appears to be activated at the earliest phases of prostate cancer (e.g., in tumor-initiating cells) in prostatic intraepithelial neoplasia, a key precursor lesion to invasive prostatic adenocarcinoma. The initiation and early progression of prostate cancer can be recapitulated in genetically engineered mouse models, permitting a richer understanding of the cause and effects of loss of tumor suppressors and activation of MYC. The combination of studies using human tissues and mouse models paints an emerging molecular picture of prostate cancer development and early progression. This picture reveals that MYC contributes to disease initiation and progression by stimulating an embryonic stem cell-like signature characterized by an enrichment of genes involved in ribosome biogenesis and by repressing differentiation. These insights pave the way to potential novel therapeutic concepts based on MYC biology.

23 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YLYao-Xin Lin
Yao-Xin Lin
YWYi Wang
Yi Wang
Jianxun DingJianxun Ding
Jianxun Ding
AJAiping Jiang
Aiping Jiang
JWJie Wang
Jie Wang
JSJinjun Shi
Jinjun Shi
The restoration of tumor suppressor PTEN by synthetic mRNA nanoparticles sensitizes Pten -null or mutated tumors to immune checkpoint blockade therapy.

15 June 2014 in Genes & Development
Verified
Journal Article
Open access
PDF file
FCFrieda Chan
Frieda Chan
MOMelissa J. Oatley
Melissa J. Oatley
AKAmy V. Kaucher
Amy V. Kaucher
QYQi-En Yang
Qi-En Yang
CBCharles J Bieberich
Charles J Bieberich
JOJon M. Oatley
Jon M. Oatley
The maintenance of cycling cell lineages relies on undifferentiated subpopulations consisting of stem and progenitor pools. Features that delineate these cell types are undefined for many lineages, including spermatogenesis, which is supported by an undifferentiated spermatogonial population. Here, we generated a transgenic mouse line in which spermatogonial stem cells are marked by expression of an inhibitor of differentiation 4 (Id4)-green fluorescent protein (Gfp) transgene. We found that Id4-Gfp+ cells exist primarily as a subset of the type Asingle pool, and their frequency is greatest in neonatal development and then decreases in proportion during establishment of the spermatogenic lineage, eventually comprising ∼2% of the undifferentiated spermatogonial population in adulthood. RNA sequencing analysis revealed that expression of 11 and 25 genes is unique for the Id4-Gfp+/stem cell and Id4-Gfp−/progenitor fractions, respectively. Collectively, these findings provide the first definitive evidence that stem cells exist as a rare subset of the Asingle pool and reveal transcriptome features distinguishing stem cell and progenitor states within the mammalian male germline.

18 February 2011 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
TLTamara L Lotan
Tamara L Lotan
NGNilesh S Gupta
Nilesh S Gupta
WWWenle Wang
Wenle Wang
ATAntoun Toubaji
Antoun Toubaji
MHMichael C Haffner
Michael C Haffner
GNGeorge J Netto
George J Netto